Innoviva, Inc. Common Stock
INVAInnoviva, Inc. is a biotechnology company focused on the development and commercialization of respiratory and other specialty healthcare products. It primarily licenses its portfolio of pharmaceutical products and intellectual property to partner companies, with a strong emphasis on inhaled therapeutics for conditions like asthma and COPD. The company leverages its expertise in respiratory medicine to generate royalty revenue and support its strategic growth initiatives.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 30, 2015 | $0.25 | 2015-09-08 | 2015-09-10 |
| June 30, 2015 | $0.25 | 2015-06-10 | 2015-06-12 |
| March 31, 2015 | $0.25 | 2015-03-10 | 2015-03-12 |
| December 23, 2014 | $0.25 | 2014-11-21 | 2014-11-25 |
| September 18, 2014 | $0.25 | 2014-08-26 | 2014-08-28 |
Dividends Summary
- Consistent Payer: Innoviva, Inc. Common Stock has rewarded shareholders with 5 dividend payments over the past 1 years.
- Total Returned Value: Investors who held INVA shares during this period received a total of $1.25 per share in dividend income.
- Latest Payout: The most recent dividend of $0.25/share was paid 3768 days ago, on September 30, 2015.
- Yield & Schedule: INVA currently pays dividends quarterly with an annual yield of 5.09%.
- Dividend Growth: Since 2014, the dividend payout has grown by 0.0%, from $0.25 to $0.25.
- Dividend Reliability: INVA has maintained or increased its dividend for 5 consecutive payments.
Company News
Two biotech companies are highlighted as standout investments for 2026. Axsome Therapeutics has strong late-stage pipeline developments with FDA acceptance of supplemental applications for AXS-05 in Alzheimer's agitation treatment and support for AXS-12 for narcolepsy, with 19 of 20 analysts rating it a Buy and targeting 8% upside. Innoviva recei...
Innoviva reported Q2 2025 earnings with $0.77 EPS and $100.3 million revenue, exceeding analyst expectations. Specialty therapeutics sales increased 54% year-over-year, driven by new product launches like GIAPREZA and ZEVTERA, while operating income declined due to increased R&D expenses.
Basilea Pharmaceutica Ltd has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc. for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States.
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royalties and healthcare assets. The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We ...
